InvestorsHub Logo
Followers 42
Posts 4066
Boards Moderated 0
Alias Born 05/16/2006

Re: None

Thursday, 11/09/2006 12:38:11 PM

Thursday, November 09, 2006 12:38:11 PM

Post# of 262
Dynatronics Announces 09/30/06 Quarterly Results

SALT LAKE CITY, Nov. 9 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced results for its first fiscal quarter ended September 30, 2006. Sales for the quarter were $4,139,057, compared to $4,358,428 in the prior year period. Net loss for the quarter was $175,008 ($.02 per share), compared to a net loss of $22,321 ($.00 per share) in the first quarter of the previous year.

'The first quarter of fiscal year 2007 was challenging,' stated Kelvyn H. Cullimore Jr., company chairman and president. 'Increased sales of infrared light therapy products were offset by decreased sales of older 50 Series devices and Synergie aesthetic devices. In addition, we incurred heavy R&D expenses in completing the development of the new Dynatron X3 light therapy device and the DX2 combination decompression/light therapy units, both of which were introduced during the quarter. We were able to ship the DX2 in the last two weeks of the quarter, but due to the short time frame, we saw only limited sales of this important new product before the end of the quarter.'

Another factor affecting the comparison between first quarter results of the current and the previous year was the one-time $57,000 gain during last year's first quarter from the sale of an investment.

To improve overall operations, Dynatronics' management is implementing a four-fold strategy focused on (1) boosting marketing efforts through new sales incentive programs; (2) reducing labor expenses; (3) enhancing product profit margins through improved manufacturing processes; and (4) continuing development of new, state-of-the-art products for future growth.

'We believe this four-fold strategy will enable us to address short-term profitability without jeopardizing long-term growth,' added Cullimore. 'We've already begun to implement this four-fold strategy with the introduction of several new sales incentive programs and have identified a number of improvements that can be made to lower our manufacturing costs.'

'We look forward to improving our financial results by generating a full quarter of sales from the DX2 decompression/light therapy unit,' said Larry K. Beardall, executive vice president of sales and marketing. 'We're hearing encouraging reports from the field regarding the benefits patients are experiencing from the combination of decompression and light therapy. The introduction of the new T3 and T4 treatment tables, scheduled for early in the third fiscal quarter, are also expected to improve results. In addition, our distributors are excited and motivated by the new incentive programs we've introduced.'

A summary of the financial results for the quarter ended September 30,
2006, follows:

Summary Selected Financial Data
Income Statement Highlights
Quarter Ended
September 30,
2006 2005

Net sales $4,139,057 $4,358,428
Cost of sales 2,646,900 2,769,844
Gross profit 1,492,157 1,588,584
SG&A expenses 1,261,145 1,243,125
R&D expenses 478,084 413,605
Operating loss (247,072) (68,146)

Other income (expense) (37,495) 31,852

Loss before income taxes (284,567) (36,294)
Income tax benefit (109,559) (13,973)
Net loss $(175,008) $(22,321)
Net loss per share (diluted) $(.02) $.00



Balance Sheet Highlights

September 30, June 30,
2006 2006
Cash $247,006 $423,184
Accounts Receivable 2,919,455 3,022,991
Inventories 5,142,825 4,982,990
Total current assets 9,693,157 9,605,497
Total assets $14,523,185 $14,523,655

Accounts payable $685,028 $593,016
Accrued expenses 523,569 536,131
Total current liabilities 2,454,334 2,215,350
Total liabilities 5,044,458 4,852,613
Total liabilities and equity $14,523,185 $14,523,655



Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

SOURCE Dynatronics Corporation

Source: PR Newswire (November 9, 2006 - 11:00 AM EST)

DIVERSIFICATION IS RULE #1 -- YOU ALONE ARE RESPONSIBLE FOR YOUR INVESTMENT DECISIONS -- ALWAYS CONDUCT YOUR OWN DUE DILIGENCE -- NEVER INVEST MORE THAN YOU CAN AFFORD TO LOSE -- HOPE IS NOT AN INVESTMENT STRATEGY -- PATIENCE !!!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DYNT News